Synthis Therapeutics is a NY-based biotech company developing the next generation of immunomodulatory antibody drug conjugates (ADCs) for cancer patients. Our lead drug, SYN101, is a first in class, immune cell targeted, ADC that selectively and safely drives tumor clearance with measurable PD markers and T cell activation, in multiple tumor models in vivo. Synthis is the only company developing immunomodulatory therapies that block immune suppression and have issued patents on the platform. We are currently raising a $35M Series A for IND enabling studies and first in human safety and clinical signal.
AvantGuard is blurring the line between antibiotics, antiseptics, and disinfectants to create your first line of defense against all pathogens on all surfaces, including your skin, so we can reserve the use of oral antibiotics for when we need them most. Our mission is to replace topical antibiotics with a nature-inspired, proven biocide that is safe, kills all pathogens (viruses, bacteria, and fungi) and has no history of resistance generation. AvantGuard’s™ proprietary combinations of specialty molecules and polymers are customized to protect surfaces and skin in a variety of applications, ensuring a healthier and safer world.
Lime Therapeutics is discovering precision medicines for lipid-mediated targets in cancer, metabolic disorders, and neurodegenerative diseases. Combined, these represent a $290B market. We blend world-class expertise in nanotechnology with translational experience in discovering and developing new therapeutic targets. Lime is developing technology spun out of Dr. Dan Heller’s Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center, and is led by Dr. Shardule Shah, an immuno-oncology PhD and Harvard MBA with deep biotech startup experience. Lime's scientific advisory board consists of world-renowned faculty from MIT, UCSF, Cornell, and Memorial Sloan Kettering, and our business advisory board includes seasoned biotech CEOs, including one with a $2B+ exit. The time for lipid-targeting therapeutics is now, and we look forward to discussing with you how we are meeting this need.
Autism rates keep rising worldwide, the costs are skyrocketing, yet currently there are no FDA approved pharmacological or device treatments that target its core symptoms. JelikaLite is developing Cognilum -– a transformational neuromodulation platform combining non-invasive wearable brain stimulation medical device with machine learning personalization, rapidly improving children’s speech, responsiveness and socialization. To date - we built a functioning prototype, conducted 3 successful clinical studies with children, received FDA breakthrough device designation, received National Science Foundation grant, have patents, have global commercialization partners and raised over $2MM. Our vision is to provide non-invasive, personalized and effective treatment to children affected by neurological disorders worldwide. We are currently raising a Seed round, to complete the Pivotal clinical trial for FDA de-novo submission.
Nephrogen is a biotech company in Manhattan developing curative gene therapies for kidney diseases using CRISPR-Cas gene editing and adeno-associated virus (AAV). Our initial focus is on polycystic kidney disease (PKD), which affects 600,000 Americans and has no effective treatment or cure. Nephrogen was founded by Demetri Maxim with scientific support from George Church at Harvard Medical School and Terry Watnick at the NIH PKD Center. Demetri is a Stanford-trained computational biologist who was born with PKD and has dedicated his life to developing a cure starting when he was 14 years old.
DirectSeq Biosciences, Inc. (DSI), a pioneering biotech startup, is thrilled to announce the launch of our direct RNA sequencing business. We lead the genomic industry with our state-of-the-art mass spectrometry (MS)-based sequencing technologies, enabling comprehensive sequencing of RNA modifications and decoding the complete RNA sequence. Our groundbreaking technologies go beyond the limitations of conventional high-throughput sequencing methods. In addition to decoding the four canonical nucleotides, we can identify over 170 different types of modified nucleotides in RNA. Developed at New York Tech, our technologies have received significant support, including over $6 million in research grants from the National Institutes of Health (NIH), including prestigious Center and R01 grants. Our customer base encompasses researchers in academia, biopharmaceutical companies developing RNA-based vaccines and therapeutics, FDA and federal agencies overseeing RNA drugs, as well as clinics focused on RNA-based diagnosis and treatment.
Developing novel therapeutics to treat heart failure
Our intervention will consist of sessions with AI-based Conversational Autonomous Therapists (CATs) to assist families in caring for their family members with Alzheimer's disease and related diseases (ADRD), by augmenting the treatment of depression of caregivers or informal support partners of such patients. More than 11 million family members and other unpaid caregivers provided an estimated 15.3 billion hours of care to people with ADRD in 2020. Unpaid dementia caregiving was valued at $256.7 billion in 2020. Its costs, however, extend to family caregivers’ increased emotional stress and depression, often stemming from the experience of seeing relatives in a trajectory of cognitive decline and with a decreased ability to meaningfully communicate and interact. Research has substantiated the often lower level provision of care to ADRD patients when caregivers experience depression. The global shortage of therapists has been exacerbated by the pandemic. By providing ADRD caregivers with a human-like therapeutic experience remotely, 24/7, at the click of an icon, as a therapy augmentation, we will alleviate depression they’re experiencing. Our CATs provide for caregivers to engage in conversation, in contrast with existing interventions that limit patients to discrete multiple choice responses.
Neuralina Therapeutics is a biopharmaceutical start-up focused on the discovery and development of novel and repurposed drugs for treatment of central nervous system disorders including Parkinson’s disease, Rett Syndrome, and Restless Leg Syndrome. Neuralina Therapeutics’ flagship therapy, Zyxtine™, represents the next evolution for management of levodopa-induced dyskinesia, a complication characterized by uncontrollable, hyperkinetic movements that occur in as many as 9 of 10 people with Parkinson's disease. In contrast to the available treatments which target the dopamine neurons that degenerate and die in Parkinson's disease, Zyxtine™ regulates the serotonin neurons that overcompensate for this loss - ultimately blocking dyskinesia and restoring unhindered movement. Neuralina Therapeutics has incorporated patient and provider feedback regarding the swallowing challenges common in Parkinson's disease that are often exacerbated by dyskinesia and will formulate Zyxtine into the Zydis® orally disintegrating tablet platform to overcome this hurdle. Using the 505(b)2 regulatory approval pathway, Neuralina Therapeutics will rapidly accelerate Zyxtine™ into the clinic by leveraging a wealth of non-clinical and clinical data, our partner’s manufacturing and distribution infrastructure, and our close ties to clinical investigators at the Muhammad Ali Parkinson's Center.
Innovene is developing the world’s first antiviral to combat the unbearable burden of HPV disease. By targeting infection, Innovene’s will prevent HPV disease at its source, before it develops into precancer or cancer. See website here http://www.innovenemed.com/